RCS - OptiBiotix Health - New health claims for SlimBiome in Australia

OptiBiotix HealthAnnouncement

17/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221017:nRSQ9972Ca&default-theme=true

RNS Number : 9972C  OptiBiotix Health PLC  17 October 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

New health claims for SlimBiome® in Australia

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, cardiovascular disease and diabetes, announces
additional new health claims for SlimBiome® containing products in
Australia.  This will help to further differentiate and advance their market
share in health & wellness, sports nutrition and weight management
markets.

 

In accordance with the Australia New Zealand Food Standards Code ("FSANZ"),
OptiBiotix has completed a systematic review of the scientific literature for
its prebiotic weight management aid SlimBiome® which allows it to make four
new general level health claims on their product packaging and general
advertising. These claims are:

 

-     SlimBiome® contributes to the enhancement of the feelings of
fullness and helps you stay fuller for longer

-     SlimBiome® contributes to the enhancement of satiety, feelings of
fullness, reduced feelings of hunger, food cravings and the desire to eat

-   SlimBiome® supports digestive health by maintaining and/or improving the
gut microbiome, by promoting gut microbiome diversity and a healthy intestinal
bacterial balance

-     SlimBiome® supports and improves digestive health by promoting the
growth and diversity of beneficial bacteria in the gut

 

The systematic review evaluates whether there is sufficient evidence to
establish a relationship between a food or property of food and a health
effect (food-health relationship) and includes an extensive review and ranking
of data, assessment of quality of the studies and preparation of a dossier to
meet requirements of Schedule Six of the FSANZ.

 

The extensive dossier built by OptiBiotix enables OptiBiotix partners in
Australia to notify FSANZ and apply these claims to communicate the key Unique
Selling Points (USPs) of their products containing SlimBiome® which will help
differentiate their products from, and gain market share against, mainstream
competitors and stand out in the health & wellness, weight management and
sports nutrition categories.

 

SlimBiome® is a patented prebiotic weight management aid used as such or in
formulated products in the health & wellness, sports nutrition and weight
management categories. SlimBiome® is supported by independent human clinical
studies which show it reduces hunger, cravings for sweet and savoury foods,
and fat intake. It helps people stick to the diet plan they have undertaken.
Consumers who used SlimBiome® in combination with a calorie restricted diet
experience a relief from feeling hungry and have fewer cravings for food,
leading to easier and more sustainable dieting and lose on average an
additional 2kg of fat per month, improving body composition.

 

SlimBiome® has achieved multiple industry awards. The three major awards are:
European Weight Management Ingredient of the Year (NutraIngredients 2018),
Asia Weight Management Ingredient of the Year (NutraIngredients 2019), and
most recently, best weight management product in the USA (Nutrition Industry
Executive Award 2021). Depending on the market, SlimBiome® is also marketed
under tradenames OptiBiome® and LeanBiome®.

 

René Kamminga, CEO of OptiBiotix Limited, a wholly owned subsidiary of
OptiBiotix Health plc, commented: "This important step forward enables our
customers in Australia to notify FSANZ through a simple process and make
health claims that are meaningful to their consumers that clearly
differentiate their products from mainstream competition. It demonstrates our
commitment to grow with our chosen customers and this will further accelerate
the growth in our market position in Australia both online and offline in
pharmacy and retail channels. SlimBiome® now carries health claims with the
European Food Safety Authority (EFSA), with Health Canada and FSANZ, some of
the most challenging regulatory environments worldwide. It truly gives brands
in health & wellness, sports nutrition and weight management the science
to stand out in their category. I want to specifically thank our scientific
and regulatory team who put a great effort in to make this possible."

 

For further information, please contact:

 

 OptiBiotix Health plc                                  www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cenkos Securities plc (Broker)                         Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                        Mob: 07876 741 001
 Anna Dunphy

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUSAVRUBURAAA